PlainPharmaWatch

CMS Open Payments · Program Year 2024

Boehringer Ingelheim RCV GmbH & Co KG

Boehringer Ingelheim RCV GmbH & Co KG reported $126,893.79 across General Payments, Research, and Ownership to 12 physicians and teaching hospitals across 70 transactions.

See the rankings → How this is sourced
$126.9K
All-tracks total
70
Transactions
12
Recipients
−$148.3K
General Payments vs PY2023

Boehringer Ingelheim RCV GmbH & Co KG reported $126,893.79 across all CMS Open Payments tracks (General + Research + Ownership) to 12 physicians and teaching hospitals in Program Year 2024 - ranking #1117 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $63,681.10, averaging $10.6K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer boehringer-ingelheim-rcv-gmbh-co-kg Boehringer Ingelheim RCV GmbH & Co KG

$126.9K · #1117/1,925 · 0.0% industry · PY2024

  • TOT $126.9K
  • RANK #1117
  • SHARE 0.0%
  • TXN 70
  • RCP 12
  • CAT 3
  • GEN $63.7K
  • ΔGEN −$148.3K
  • TOP1 33.4%
  • PY 2024

Volume peers

Nearest volume peer: Oculus Surgical Inc. ($127.1K)

Southern Implants North Amer…$127.2KOculus Surgical Inc.$127.1KBoehringer Ingelheim RCV Gmb…$126.9KReflow Medical Inc$126.3KFEMSelect Inc.$126.2K
All-tracks payment totals near Boehringer Ingelheim RCV GmbH & Co KG (CMS Open Payments PY2024)

Boehringer Ingelheim RCV GmbH & Co KG sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Boehringer Ingelheim RCV GmbH & Co KG's CMS-reported General Payments decreased by $148.3K (−70.0%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BOEHRINGER INGELHEIM RCV GMBH & CO KGPY2023: BOEHRINGER INGELHEIM RCV GMBH & CO KGPY2024: Boehringer Ingelheim RCV GmbH & Co KG. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$212.0KPY2024$63.7K
PY2023
$212,030.09
PY2024
$63,681.10

What the Data Shows for Boehringer Ingelheim RCV GmbH & Co KG

$126,893.79: that is what Boehringer Ingelheim RCV GmbH & Co KG reported in payments to 12 physicians and teaching hospitals during Program Year 2024, spread across 70 transactions ($1.8K per transaction, $10.6K per recipient). The company sits at rank #1117 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 3 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $29.9K across 5 transactions, 46.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 3 types of general payments, Boehringer Ingelheim RCV GmbH & Co KG's largest category was "Compensation for Services Other Than Consulting" at $29.9K - 46.9% of General Payments.

How Boehringer Ingelheim RCV GmbH & Co KG divides its payments

General-payment categories, ordered by reported total

1. Compensation for Services…$29.9K2. Travel and Lodging$20.8K3. Consulting Fee$13.0K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $29.9K 5
Travel and Lodging $20.8K 5
Consulting Fee $13.0K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $61,731.10 (96.9%) of $63,681.10 in this company's General Payments records across 6 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Boehringer Ingelheim RCV GmbH & Co KG

The five named recipients with the highest reported General Payments from this company

Justin M Oldham$21.3KJaved Butler$20.0KMark J Ratain$11.1KDeepak Bhatt$5.6KAdrian Felipe Hernandez$3.9K
  1. 1

    Justin M Oldham

    $21,267.62 across 4 reported transactions

  2. 2

    Javed Butler

    $19,998.48 across 4 reported transactions

  3. 3

    Mark J Ratain

    $11,050.00 across 1 reported transactions

  4. 4

    Deepak Bhatt

    $5,565.00 across 1 reported transactions

  5. 5

    Adrian Felipe Hernandez

    $3,850.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Boehringer Ingelheim RCV GmbH & Co KG's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Boehringer Ingelheim RCV GmbH & Co KG.

Aidoc Medical Ltd

HHI 2529

Oxford Performance Materials, Inc.

HHI 2520

Avirmax Biopharma, Inc

HHI 2519

Skye Orthobiologics LLC

HHI 2533

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Boehringer Ingelheim RCV GmbH & Co KG.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Boehringer Ingelheim RCV GmbH & Co KG's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.